Tatva Chintan Pharma Chem Q2 FY27: PAT ₹159.81 Cr & Rev ₹1,467.02 Cr

1 Financial Results 🔴 High Importance Neutral 📄 PDF

Investor Takeaways

Revenue of ₹1,467.02 crores reported for Q1 FY2026, up from ₹105.46 crores in Q1 FY25.

Net profit of ₹159.81 crores recorded, compared to ₹5.21 crores in Q1 FY25.

Board approved ₹200 crores investment for greenfield capacity expansion in Dahej, Gujarat.

Borrowing limits increased to ₹1,000 crores.

Three directors reappointed for three-year terms starting 1 February 2027.

Limited review report from NDJ & Co included; SEBI disclosures filed.

⚠️ No specific risks identified in this filing.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹1,467.02 Cr	+397.8%
Net Profit	₹159.81 Cr	+2,958.7%
EBITDA	Not available	N/A
EPS	Not available	N/A
OPM	Not available	N/A

What Changed

The company reported a significant turnaround in Q1 FY2026 with revenue increasing to ₹1,467.02 crores from ₹105.46 crores in the same quarter last year, and net profit rising to ₹159.81 crores from ₹5.21 crores. This growth reflects strong operational performance. The board approved a ₹200 crores investment for capacity expansion at a new greenfield unit in Dahej, Gujarat, and increased borrowing limits to ₹1,000 crores to support future funding needs. Director reappointments were also approved for three-year terms starting 1 February 2027. The filing includes a limited review report from NDJ & Co and complies with SEBI disclosure requirements. The company’s market capitalization stands at ₹3,079.1 crores with a P/E ratio of 215.43.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Tatva Chintan Pharma Chem Limited	215.43	N/A	N/A	3,079.1
Solar Industries India Limited	132.27	N/A	N/A	1,56,674.48
Pidilite Industries Limited	75.73	N/A	N/A	1,49,378.89
SRF Limited	69.51	N/A	N/A	79,723.46

Tatva Chintan Pharma Chem has a significantly higher P/E ratio compared to peers, indicating market expectations of higher future growth or earnings potential, though absolute scale remains smaller.

Risks & Concerns

No specific risks identified in this filing.

Quarterly Trend

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	OPM%
Q3FY25	85.9	0.14	8.22
Q2FY25	83.49	-0.66	6.68
Q1FY25	105.46	5.21	11.96
Q4FY24	98.27	9.61	15.88

The company’s revenue and profitability show seasonal volatility, with Q1 FY25 being the most profitable quarter in the recent past before the current Q1 FY26 results. OPM has fluctuated between 6.68% and 15.88% over the last four quarters. The latest quarter’s performance marks a substantial improvement over the prior year’s Q1, though profitability remains sensitive to operational and market conditions.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

📢 Key Event
Q1FY27 revenue up 43% YoY to ₹1,671 crores

🔄 What Changed
Revenue +43% YoY; PAT +140% YoY; EBITDA +86% YoY; PAT margin 10%; EBITDA margin 19%

💡 Investor Takeaway
Strong top-line and bottom-line growth with expanding margins signals healthy execution and scalable specialty chemical business model.

Tatva Chintan Pharma Chem Limited reported Q1FY27 revenue of ₹1,671 crores, up 43% YoY, driven by strong growth across all product segments. PAT rose 140% YoY to ₹160 crores, with PAT margin expanding to 10%. EBITDA increased 86% YoY to ₹323 crores, and EBITDA margin improved to 19%. The company highlighted its sustainable chemistry focus and green manufacturing practices as key differentiators. (68 words)

📊 Stock Analysis — TATVA ✨ Ask AI About This

About Tatva Chintan Pharma Chem Limited (TATVA)

Chemicals · Chemicals & Petrochemicals · Listed on NSE

Market Cap: ₹3,079.1 Cr P/E: 215.4

View full TATVA stock details →

📡 Get AI alerts when TATVA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track TATVA — Free

💡 Ask AI about this filing

"What is the expected revenue contribution from the new Dahej capacity expansion?" "How will the increased borrowing limit impact the company's debt-to-equity ratio?" "What is the projected timeline for commissioning the new greenfield manufacturing unit?"

Ask AI Free →

📊 More TATVA filings

See all TATVA filings →

🔥 Also filed on 17 July 2026

WIPRO Wipro Limited Financial Results TATAELXSI Tata Elxsi Limited Financial Results TATATECH Tata Technologies Limited Financial Results JAYNECOIND Jayaswal Neco Industries Limited Financial Results FEDERALBNK The Federal Bank Limited Corporate Action UYFINCORP U. Y. Fincorp Limited Insider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when TATVA files new disclosures

Track TATVA filings, board meetings, and corporate actions. Free email alerts at 5 PM.